HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER

摘要

The present application provides a compound that is N-(2-amino-1-(3 -chloro-5 -fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide (shown below), or a pharmaceutically acceptable salt or stereoisomer thereof. Also provided are methods for preparing the compound. The compound is useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of the compound, the compouns is effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using the compound and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.